These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9607574)

  • 1. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
    Pizzorno G; Yee L; Burtness BA; Marsh JC; Darnowski JW; Chu MY; Chu SH; Chu E; Leffert JJ; Handschumacher RE; Calabresi P
    Clin Cancer Res; 1998 May; 4(5):1165-75. PubMed ID: 9607574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
    Sommadossi JP; Cretton EM; Kidd LB; McClure HM; Anderson DC; el Kouni MH
    Cancer Chemother Pharmacol; 1995; 37(1-2):14-22. PubMed ID: 7497584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.
    Davis ST; Joyner SS; Chandrasurin P; Baccanari DP
    Biochem Pharmacol; 1993 Jan; 45(1):173-81. PubMed ID: 8424810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzylacyclouridine. Pharmacokinetics, metabolism and biochemical effects in mice.
    Darnowski JW; Handschumacher RE
    Biochem Pharmacol; 1988 Jul; 37(13):2613-8. PubMed ID: 3390221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.
    Darnowski JW; Handschumacher RE
    Cancer Res; 1985 Nov; 45(11 Pt 1):5364-8. PubMed ID: 4053009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
    Martin DS; Stolfi RL; Sawyer RC
    Cancer Chemother Pharmacol; 1989; 24(1):9-14. PubMed ID: 2720896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine.
    Darnowski JW; Handschumacher RE; Wiegand RA; Goulette FA; Calabresi P
    Biochem Pharmacol; 1991 Jun; 41(12):2031-6. PubMed ID: 2039551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5-benzylacyclouridine.
    Holland SK; Bergman AM; Zhao Y; Adams ER; Pizzorno G
    Magn Reson Med; 1997 Dec; 38(6):907-16. PubMed ID: 9402191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors.
    Liu M; Cao D; Russell R; Handschumacher RE; Pizzorno G
    Cancer Res; 1998 Dec; 58(23):5418-24. PubMed ID: 9850074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.
    Orr GF; Musso DL; Boswell GE; Kelley JL; Joyner SS; Davis ST; Baccanari DP
    J Med Chem; 1995 Sep; 38(19):3850-6. PubMed ID: 7562916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy.
    Ashour OM; Al Safarjalani ON; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
    Cancer Chemother Pharmacol; 2000; 45(5):351-61. PubMed ID: 10803917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver.
    Monks A; Ayers O; Cysyk RL
    Biochem Pharmacol; 1983 Jul; 32(13):2003-9. PubMed ID: 6870929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
    Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzylacyclouridine enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines.
    Yee LK; Chu E; Pan BC; Chu SH; Chen TM; Lipsky MH; Chu MY; Calabresi P
    Pharmacology; 1998 Feb; 56(2):80-91. PubMed ID: 9494066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy.
    Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
    Cancer Chemother Pharmacol; 2000; 46(3):235-40. PubMed ID: 11021741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of nucleoside transport in murine lymphoma L5178Y cells and human erythrocytes by the uridine phosphorylase inhibitors 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine.
    Lee KH; el Kouni MH; Chu HS; Cha S
    Cancer Res; 1984 Sep; 44(9):3744-8. PubMed ID: 6744292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
    Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines.
    Temmink OH; de Bruin M; Turksma AW; Cricca S; Laan AC; Peters GJ
    Int J Biochem Cell Biol; 2007; 39(3):565-75. PubMed ID: 17098463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy.
    Al Safarjalani ON; Zhou XJ; Naguib FN; Shi J; Schinazi RF; el Kouni MH
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):389-97. PubMed ID: 11761457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of uridine phosphorylase. Synthesis and structure-activity relationships of aryl-substituted 1-((2-hydroxyethoxy)methyl)-5-(3-phenoxybenzyl)uracil.
    Orr GF; Musso DL; Kelley JL; Joyner SS; Davis ST; Baccanari DP
    J Med Chem; 1997 Apr; 40(8):1179-85. PubMed ID: 9111291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.